Novel psoriasis biologic wows with jaw-dropping results

AMSTERDAM– The spectacular long-term efficacy achieved with a novel biologic agent for psoriasis in a first-in-humans, proof-of-concept study has raised the prospect of clinical outcomes continuing...

Field of Interest: Dermatology
Type: News Item

Select biologics for dose escalation in psoriasis

SONOMA, CALIF.– Data support dosage escalation or intensification for patients who don’t respond to biologic therapy for psoriasis, but only for three of the four biologic agents available in the...

Field of Interest: Dermatology
Type: News Item

In psoriasis, is pushing for PASI 90 really worthwhile?

AMSTERDAM – Does pushing for a PASI 90 response instead of settling for a PASI 75 matter to patients being treated for moderate-to-severe chronic plaque psoriasis? You bet it does, Dr. Mark G....

Field of Interest: Dermatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.